The Inhibition by Oxaliplatin, a Platinum-Based Anti-Neoplastic Agent, of the Activity of Intermediate-Conductance Ca2+-Activated K+ Channels in Human Glioma Cells

The Inhibition by Oxaliplatin, a Platinum-Based Anti-Neoplastic Agent, of the Activity of Intermediate-Conductance Ca2+-Activated K+ Channels in Human Glioma Cells

Oxaliplatin (OXAL) is a third-generation organoplatinum which is effective against advanced cancer cells including glioma cells. How this agent and other related compounds interacts with ion channels in glioma cells is poorly understood. OXAL (100 µM) suppressed the amplitude of whole-cell K+ curren...

Full description

Bibliographic Details
Main Authors:	Mei-Han Huang, Yan-Ming Huang, Sheng-Nan Wu
Format:	Article
Language:	English
Published:	Cell Physiol Biochem Press GmbH & Co KG 2015-10-01
Series:	Cellular Physiology and Biochemistry
Subjects:	K+ current Intermediate-conductance Ca2+-activated K+ channel Oxaliplatin Glioma cell
Online Access:	http://www.karger.com/Article/FullText/430404

Similar Items

Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells
by: Poh-Shiow Yeh, et al.
Published: (2016-05-01)

Depressive effectiveness of vigabatrin (γ-vinyl-GABA), an antiepileptic drug, in intermediate-conductance calcium-activated potassium channels in human glioma cells
by: Te-Yu Hung, et al.
Published: (2021-01-01)

Evidence of Decreased Activity in Intermediate-Conductance Calcium-Activated Potassium Channels During Retinoic Acid–Induced Differentiation in Motor Neuron–Like NSC-34 Cells
by: Pei-Chun Chen, et al.
Published: (2018-08-01)

Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe2+ and boosting Fenton reaction
by: Xue Li, et al.
Published: (2024-03-01)

Midazolam’s Effects on Delayed-Rectifier K<sup>+</sup> Current and Intermediate-Conductance Ca<sup>2+</sup>-Activated K<sup>+</sup> Channel in Jurkat T-lymphocytes
by: Ning-Ping Foo, et al.
Published: (2021-07-01)

Actions of FTY720 (Fingolimod), a Sphingosine-1-Phosphate Receptor Modulator, on Delayed-Rectifier K<sup>+</sup> Current and Intermediate-Conductance Ca<sup>2+</sup>-Activated K<sup>+</sup> Channel in Jurkat T-Lymphocytes
by: Wei-Ting Chang, et al.
Published: (2020-10-01)

Characterization of Perturbing Actions by Verteporfin, a Benzoporphyrin Photosensitizer, on Membrane Ionic Currents
by: Mei-Han Huang, et al.
Published: (2019-08-01)

DCEBIO facilitates myogenic differentiation via intermediate conductance Ca2+ activated K+ channel activation in C2C12 myoblasts
by: Shoko Tanaka, et al.
Published: (2017-04-01)

Oxaliplatin-Associated Amaurosis Fugax
by: Kimitoshi Kubo, et al.
Published: (2021-06-01)

Inhibitory actions by ibandronate sodium, a nitrogen-containing bisphosphonate, on calcium-activated potassium channels in Madin–Darby canine kidney cells
by: Sheng-Nan Wu, et al.
Published: (2015-01-01)

LY294002 Inhibits Intermediate Conductance Calcium-Activated Potassium (KCa3.1) Current in Human Glioblastoma Cells
by: Concetta Caglioti, et al.
Published: (2022-01-01)

Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1
by: Corinna J. Mohr, et al.
Published: (2019-01-01)

Establishment of the menthol test as a clinical evaluation method for oxaliplatin-induced neuropathy
by: Yeongcheol Cheong, et al.
Published: (2022-08-01)

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids
by: Qingguo Li, et al.
Published: (2021-11-01)

Exploring the Impact of BK<sub>Ca</sub> Channel Function in Cellular Membranes on Cardiac Electrical Activity
by: Yin-Chia Chen, et al.
Published: (2024-01-01)

Tumor-Associated Microenvironment of Adult Gliomas: A Review
by: Vincenzo Di Nunno, et al.
Published: (2022-07-01)

Characterization and Chemical Synthesis of Cm39 (α-KTx 4.8): A Scorpion Toxin That Inhibits Voltage-Gated K<sup>+</sup> Channel K<sub>V</sub>1.2 and Small- and Intermediate-Conductance Ca<sup>2+</sup>-Activated K<sup>+</sup> Channels K<sub>Ca</sub>2.2 and K<sub>Ca</sub>3.1
by: Muhammad Umair Naseem, et al.
Published: (2023-01-01)

Adsorption of Oxaliplatin by Hydroxyapatite
by: Papageorgiou A., et al.
Published: (2007-12-01)

Increase in spleen volume as a predictor of oxaliplatin toxicity
by: El Chediak A, et al.
Published: (2018-04-01)

A severe oxaliplatin immune-induced syndrome after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC)
by: Ezanno Anne-Cecile, et al.
Published: (2022-01-01)

Mechanisms involved in the anti-tumor effects of Toosendanin in glioma cells
by: Chaochao Zhang, et al.
Published: (2021-09-01)

Oxaliplatin Causes Transient Changes in TRPM8 Channel Activity
by: Vittoria Rimola, et al.
Published: (2021-05-01)

Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats
by: Nobuaki Egashira, et al.
Published: (2021-09-01)

Activation of Nrf2 inhibits ferroptosis and protects against oxaliplatin-induced ototoxicity
by: Kai Xu, et al.
Published: (2023-09-01)

High Efficacy by GAL-021: A Known Intravenous Peripheral Chemoreceptor Modulator that Suppresses BK<sub>Ca</sub>-Channel Activity and Inhibits <i>I</i><sub>K(M)</sub> or <i>I</i><sub>h</sub>
by: Te-Ling Lu, et al.
Published: (2020-01-01)

Hederagenin suppresses glioma cell biological activities via Nur77 in vitro study
by: Yuxiang Dai, et al.
Published: (2023-03-01)

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
by: Masanobu Tsubaki, et al.
Published: (2023-04-01)

Low molecular weight fucoidan LF2 improves the immunosuppressive tumor microenvironment and enhances the anti-pancreatic cancer activity of oxaliplatin
by: Zhenzhen Deng, et al.
Published: (2024-04-01)

Oxaliplatin related lncRNAs prognostic models predict the prognosis of patients given oxaliplatin-based chemotherapy
by: Qing-nan Zhou, et al.
Published: (2023-05-01)

Role of NKCC1 Activity in Glioma K+ Homeostasis and Cell Growth: New Insights With the Bumetanide-Derivative STS66
by: Lanxin Luo, et al.
Published: (2020-07-01)

Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy
by: Guido Cavaletti, et al.
Published: (2020-05-01)

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
by: Yuanyuan Yu, et al.
Published: (2021-05-01)

Luteolin Synergistically Enhances Antitumor Activity of Oxaliplatin in Colorectal Carcinoma via AMPK Inhibition
by: Chan Ho Jang, et al.
Published: (2022-03-01)

Amifostine protects from the peripheral sensory neuropathy induced by oxaliplatin in mice
by: A.F. Pereira, et al.
Published: (2020-09-01)

Oxaliplatin-induced Sudden Hearing Loss in a Patient with Pancreatic Cancer
by: Sung Bum Kim, et al.
Published: (2020-11-01)

Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
by: Renata Ferrarotto, et al.
Published: (2013-09-01)

Clinical Analysis of Oxaliplatin-related Thrombocytopenia in Patients with Digestive System Malignancy
by: DAI Yuhong, et al.
Published: (2021-05-01)

Ca<sup>2+</sup>-Sensitive Potassium Channels
by: Razan Orfali, et al.
Published: (2023-01-01)

First reported case of ANCA-associated vasculitis induced by oxaliplatin, capecitabine, and trastuzumab
by: Bengang Huo, et al.
Published: (2023-12-01)

Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review
by: Francesca Barbin, et al.
Published: (2022-12-01)